Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide
about
Anti-cytokine therapies for primary systemic necrotizing vasculitisImmunosuppressive agents for myasthenia gravisCurrent perspectives in bladder cancer managementCurrent and future prospects in the management of granulomatosis with polyangiitis (Wegener's granulomatosis)Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy.Efficacy and safety of rituximab as maintenance therapy for relapsing granulomatosis with polyangiitis—a case seriesDiagnosis and treatment of cerebral vasculitis.Treatment of active lupus nephritis with the novel immunosuppressant 15-deoxyspergualin: an open-label dose escalation study.Malignancy risk in vasculitisTreatment of idiopathic membranous nephropathy.Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelinesFamilial and genetic risk of transitional cell carcinoma of the urinary tract.Standardised incidence ratios (SIRs) for cancer after renal transplant in systemic lupus erythematosus (SLE) and non-SLE recipients.Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment IndexUrological implications of cyclophosphamide and ifosfamide.Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studiesLymphoma risk in systemic lupus: effects of disease activity versus treatmentGlucocorticoid therapy and risk of bladder cancerLong-term outcomes in idiopathic membranous nephropathy using a restrictive treatment strategySurvival of patients with Wegener's granulomatosis diagnosed in Finland in 1981-2000.Damage assessment in ANCA-associated vasculitis.Long-term outcome of antineutrophil cytoplasmic antibody-associated small vessel vasculitis after renal transplantation.Bladder Cancer versus Hemorrhagic Cystitis: A Case of Mistaken Identity in a 34-Year-Old Male Undergoing Therapy for Granulomatosis with Polyangiitis.The 2016 Bowman Lecture Conjunctival curses: scarring conjunctivitis 30 years on.Diagnostic and therapeutic management of Churg-Strauss syndrome.Renal cancer and Wegener's granulomatosis: a case report.EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis.Pulmonary metastasis in a patient with simultaneous bladder cancer and relapsing granulomatosis with polyangiitis.Primitive Neuroectodermal Tumor and Wegener's Granulomatosis of the Kidney: A Curious Combination of Two Rare Entities.Prolonged risk of specific malignancies following cyclophosphamide therapy among patients with granulomatosis with polyangiitis.Urinary bladder cancer in Wegener's granulomatosis: is it more than cyclophosphamide?Balancing cancer risk and efficacy of using cyclophosphamide to treat idiopathic membranous nephropathy.Mortality in Wegener's granulomatosis: a bimodal pattern.Incidence and predictors of urotoxic adverse events in cyclophosphamide-treated patients with systemic necrotizing vasculitides.Beneficial Effect of Rituximab in the Treatment of Esophageal Cancer-Associated Pauci-Immune Glomerulonephritis.Intravenous cyclophosphamide in patients with chronic systemic inflammatory diseases: morbidity and mortality.Avoidance of Harm From Treatment for ANCA-Associated Vasculitis.Malignancy in Renal Transplant Recipients Exposed to Cyclophosphamide Prior to Transplantation for the Treatment of Native Glomerular Disease.Granulomatosis with polyangiitis (Wegener's granulomatosis): a rare variant of sudden natural death.Cancer in ANCA-Associated Glomerulonephritis: A Registry-Based Cohort Study.
P2860
Q24241555-67A412AF-340A-4DD3-9E1A-4B1B0916D578Q24243208-9B1CE04A-29C7-4BB6-8A5B-5B232F4C69D1Q26824914-33038390-C210-4927-A28D-E1BB7A2D299EQ27025692-5078A966-3D72-4968-A665-79576889C542Q33715801-9CA594BF-792C-42F3-9B28-77A6A808606AQ33757209-EF7A7AC2-93C3-4C88-A17A-E6E767A54708Q34156332-2504E186-EFDD-48E1-9479-D2501301F6F8Q35092872-C6F4BE7E-45CA-459D-9842-49847F09A958Q36059573-F16BF249-2EDC-4B42-A385-81D68AF6E00EQ36280345-826282DC-B2C6-4B4E-9E29-6777ECB02118Q36724093-E298B5F6-2188-4CC5-A8FE-4184864C0CECQ36951321-10390957-1E3B-450B-B6CC-41D135601FD2Q37007011-032CF847-A43A-43EB-BA6D-966DCD21BA6AQ37170449-E971A5E1-A4F8-411A-987A-413F900EFFEBQ37264407-8AFEAE34-F81A-43E0-A385-B5077BB1AB49Q37304301-B1EBA8FE-0F53-44F6-9949-2FDD45E9F08EQ37374458-80AD74D3-00BB-4439-8505-A3C2F88F7CA3Q37401519-3C1EDF32-7887-4055-9AF0-1995A11B08A4Q37411651-8C28F6A5-D776-47F1-9FA0-6D666BB66452Q37687435-502F33C9-2C3A-4F54-BFE6-0CBC7475CCA5Q38043946-80140495-C57F-4F32-A477-E83F86BA2F2FQ38082794-19068F5B-1BA2-416E-9651-8B930EB5E46AQ38230018-B19BED55-E461-4844-B441-38075B130C69Q39096598-C7CB4D8D-544A-4EA7-850E-E31EE75EAE2BQ39872550-DB8F597C-DFC8-41A6-A909-CFD875814719Q40257915-1BC48FDF-F6EC-4E10-95E5-09D92EA34E4DQ40684657-B091DA9A-971C-4D75-9841-1F8126431048Q41233706-BA4A9F05-3B5A-49B3-A88D-C6BFDF351528Q41402841-9EA37ED5-44BB-4B3C-A28A-B607B158AECBQ41733954-D793DA5A-76C1-4D5E-8840-70938A41A99BQ42161729-3E76FEAC-9C20-4B65-AC61-06E7ED227444Q42639047-A3351E7F-95F1-4FDA-AE7C-EC09B9BFF457Q44964147-495EC061-5C18-4A3C-82CE-83AFCFFBA42FQ45031657-90266702-33B9-442D-9412-8CB99678686FQ46402507-C2731AC6-C2E7-4E39-8576-6CAC2034A659Q46642259-02722E40-388A-4A4D-A6AE-0C92D84A7091Q47105115-FB650569-53E4-45F8-B0BA-2FF46F3304DEQ47599071-3FA82FE0-9B0B-4390-8C32-551FBC1CD97AQ47727879-CD3F42B9-CDAA-4720-887B-00AE09E7DAD4Q48102349-386539CA-6536-4567-B5F9-AC42AE0BCE51
P2860
Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide
description
2004 nî lūn-bûn
@nan
2004 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Urinary bladder cancer in Wege ...... d relation to cyclophosphamide
@ast
Urinary bladder cancer in Wege ...... d relation to cyclophosphamide
@en
type
label
Urinary bladder cancer in Wege ...... d relation to cyclophosphamide
@ast
Urinary bladder cancer in Wege ...... d relation to cyclophosphamide
@en
prefLabel
Urinary bladder cancer in Wege ...... d relation to cyclophosphamide
@ast
Urinary bladder cancer in Wege ...... d relation to cyclophosphamide
@en
P2093
P2860
P356
P1476
Urinary bladder cancer in Wege ...... d relation to cyclophosphamide
@en
P2093
P2860
P304
P356
10.1136/ARD.2003.019125
P407
P50
P577
2004-05-06T00:00:00Z